In March 2025, the company declared new strategies for a direct-to-consumer presenting of its Wegovy weight loss drug. The company established a completely new pharmacy, known as NovoCare, which would charge prospects $499 a month for entry to the drug, less than fifty percent the cost of the drug as a result of other pharmaceutical distribution ne